Jiangsu Kanion Pharmaceutical Co.Ltd., Lianyungang, 222001, China; State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Lianyungang, 222001, China; Modern Chinese Medicine Innovation Cluster and Digital Pharmaceutical Technology Platform, Lianyungang, 222001, China.
Jiangsu Kanion Pharmaceutical Co.Ltd., Lianyungang, 222001, China; Peking University, Beijing, 100871, China.
J Ethnopharmacol. 2021 Oct 28;279:114371. doi: 10.1016/j.jep.2021.114371. Epub 2021 Jun 26.
Diterpene Ginkgolides Meglumine Injection (DGMI) is made of extracts from Ginkgo biloba L, including Ginkgolides A, B, and K and some other contents, and has been widely used as the treatment of cerebral ischemic stroke in clinic. It can be learned from the "Compendium of Materia Medica" that Ginkgo possesses the effect of "dispersing toxin". The ancient Chinese phrase "dispersing toxin" is now explained as elimination of inflammation and oxidative state in human body. And it led to the original ideas for today's anti-oxidation studies of Ginkgo in apoptosis induced by optic nerve crush injury.
To investigate the underlying molecular mechanism of the DGMI in retinal ganglion cells (RGCs) apoptosis.
TUNEL staining was used to observe the anti-apoptotic effects of DGMI on the adult rat optic nerve injury (ONC) model, and flow cytometry and hoechst 33,342 staining were used to observe the anti-apoptotic effects of DGMI on the oxygen glucose deprivation (OGD) induced RGC-5 cells injury model. The regulation of apoptosis and MAPKs pathways were investigated with Immunohistochemistry and Western blotting.
This study demonstrated that DGMI is able to decrease the conduction time of F-VEP and ameliorate histological features induced by optic nerve crush injury in rats. Immunohistochemistry and TUNEL staining results indicated that DGMI can also inhibit cell apoptosis via modulating MAPKs signaling pathways. In addition, treatment with DGMI markedly improved the morphological structures and decreased the apoptotic index in RGC-5 cells. Mechanistically, DGMI could significantly inhibit cell apoptosis by inhibiting p38, JNK and Erk1/2 activation.
The study shows that DGMI and ginkgolides inhibit RGCs apoptosis by impeding the activation of MAPKs signaling pathways in vivo and in vitro. Therefore, the present study provided scientific evidence for the underlying mechanism of DGMI and ginkgolides on optic nerve crush injury.
银杏二萜内酯葡胺注射液(DGMI)由银杏叶提取物制成,包括银杏内酯 A、B、K 和其他一些成分,已广泛用于临床治疗脑缺血性中风。从《本草纲目》中可以了解到,银杏具有“散毒”的作用。古汉语中的“散毒”现在解释为消除人体内的炎症和氧化状态。这导致了今天对银杏在视神经挤压损伤诱导的细胞凋亡中抗氧化作用的研究。
研究 DGMI 对视网膜神经节细胞(RGC)凋亡的潜在分子机制。
TUNEL 染色观察 DGMI 对成年大鼠视神经损伤(ONC)模型的抗凋亡作用,流式细胞术和 Hoechst 33,342 染色观察 DGMI 对氧葡萄糖剥夺(OGD)诱导的 RGC-5 细胞损伤模型的抗凋亡作用。用免疫组织化学和 Western blot 研究凋亡和 MAPKs 途径的调节。
本研究表明,DGMI 可降低 F-VEP 的传导时间,并改善大鼠视神经挤压损伤的组织学特征。免疫组织化学和 TUNEL 染色结果表明,DGMI 还可以通过调节 MAPKs 信号通路抑制细胞凋亡。此外,DGMI 处理可明显改善 RGC-5 细胞的形态结构,降低细胞凋亡指数。机制上,DGMI 通过抑制 p38、JNK 和 Erk1/2 的激活,显著抑制细胞凋亡。
本研究表明,DGMI 和银杏内酯通过阻止 MAPKs 信号通路的激活,抑制体内和体外 RGC 凋亡。因此,本研究为 DGMI 和银杏内酯对视神经挤压损伤的潜在机制提供了科学依据。